栓塞加门静脉灌输CD_3 AK细胞治疗中晚期肝癌的研究

动态观察肝动脉化疗栓塞加门静脉插管化疗、灌输CD3 AK细胞治疗中晚期肝癌的临床疗效及对机体免疫功能的影响。将 2 0例中晚期肝癌随机分为A、B两组 ,A组 ( 10例 )肝动脉化疗栓塞加门静脉插管化疗、灌输CD3 AK细胞治疗 ,B组 ( 10例 )肝动脉化疗栓塞加门静脉插管化疗。另设C组 ( 10例 )肝良性肿瘤患者作为对照组。结果A组患者的细胞免疫指标 (CD3 、CD4 、CD4 /CD8、NKC、IL -2R、T淋巴细胞转化率 )及体液免疫指标 (sIL -2R、TNF -a)在术后第 1周开始迅速恢复且维持在高水平状态 (P <0 .0 5 ) ,术后第 2周、第 3周、第 4周均呈上升趋势且保持在高水平状态。B组术后细胞免疫及体液免疫功能指标在术后第 1周时较术前明显降低 (P <0 .0 5 ) ,术后第 2周开始逐渐恢复但较缓慢。A、B两组术后同期同指标相比较差异有显著性 (P <0 .0 5 )。C组外周血单个核细胞的分布及体液免疫功能指标在术前、术后相比较差异无显著性 (P >0 .0 5 ) ,但均比A、B组高。A组的临床有效率为 70 % ,B组为 40 %。结论 :肝动脉化疗栓塞加门静脉插管化疗、灌输CD3 AK细胞治疗能提高中晚期肝癌临床疗效 ,提高肿瘤的Ⅱ期切除率及迅速恢复、提高机体的免疫功能。

Study of combined effect of Hepatic arterial chemoembolisation and portal venous infusion with CD_3AK cells on patients with primary hepatic carcinoma

The puepose of this study was to dynamically observe the clinical therapeutic value and effect on hostal immunol functional changes for patients with primary hepatic carcinama, which were given hepatic arterial chemoembolisation and portal venous infusion with CD 3AK cells treatment. The methods used as follow: 20 cases of patient with primary hepatic carcinoma of primary colon origin are divided into group A and group B.In group A (10 cases), patients were given the combined hepatic arterial chemoembolisation and portal venous infusion with CD 3AK cells remedy. In group B (10 cases), patients received the combined hepatic arterial chemoembolisation only, while in group C, the control group, patients with benign neoplasm of liver were compared with those in groupA and B. Results showed that in group A, the immunity index(CD 3,CD 4,CD 3/CD 8,NKC,IL-2R,T lymphatic cell transformation rate) and basal fluid immunity index (sIL-2R. TNF-a) restore swiftly and can maintain at high level (P<0.05), the 1st week after operation, It overcame the generally low immunol ability as a result brought by surgery at early stage. While in group B, the cellular immunity and basal fluid immunol index remain obviously low (P<0.05 ), 1st week after operation, It restores normal at a lower pace after the 2nd week. In group C , the peripheral mono-nuclear blood cells distribution and basal fluid immunity index have no significant difference before and after operation (P>0.05), however, it is higher than those in group A and B . The effective rate in group A is 70%, while in group B is 40%. It could be concluded that the combined hepatic arterial chemombolisation and portal venous infusion carcinoma with CD 3AK cells therapy has markedly improved the clinical therapeutic value and patients can swiftly recover. It is also effective to enhance hostal immune function.